Loading clinical trials...
Loading clinical trials...
An Open-Label Phase 1/2 Study to Assess the Immunogenicity and Safety of a Single Prime-Boost Vaccination Schedule With a Vero Cell-Derived Whole Virus H5N1 Influenza Vaccine in Healthy Volunteers Aged 18 to 59 Years
Conditions
Interventions
Influenza vaccine (whole virion, Vero cell derived)
Influenza vaccine (whole virion, Vero cell derived)
Locations
3
Austria
General Hospital of Vienna (AKH Wien), Dept. of Clinical Pharmacology
Vienna, Austria
Espoon rokotetutkumusklinikka
Espoo, Finland
Etelä - Helsingin rokotetutkimusklinikka
Helsinki, Finland
Start Date
May 1, 2009
Primary Completion Date
October 1, 2010
Completion Date
June 1, 2011
Last Updated
October 9, 2015
NCT07291635
NCT06094010
NCT06417762
NCT06160128
NCT07396428
NCT07310472
Lead Sponsor
Alachua Government Services, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions